The ABC's of dopamine receptor partial agonists - Aripiprazole, brexpiprazole and cariprazine: The 15-min challenge to sort these agents out

International Journal of Clinical Practice

Volumn 69, Issue 11, 2015, Pages 1211-1220

  Citrome, L ^a  

^a NEW YORK MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARIPIPRAZOLE; BREXPIPRAZOLE; CARIPRAZINE; DOPAMINE RECEPTOR STIMULATING AGENT; PARTIAL AGONIST; PLACEBO; NEUROLEPTIC AGENT; PIPERAZINE DERIVATIVE; QUINOLONE DERIVATIVE; THIOPHENE DERIVATIVE;

AKATHISIA; BEHAVIOR DISORDER; BIPOLAR MANIA; CLINICAL EFFECTIVENESS; DRUG APPROVAL; DRUG CONTRAINDICATION; DRUG DOSE COMPARISON; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG HALF LIFE; DRUG INDICATION; DRUG MECHANISM; DRUG MEGADOSE; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; EDITORIAL; EXTRAPYRAMIDAL SYMPTOM; HUMAN; MAJOR DEPRESSION; MANIA; MAXIMUM PLASMA CONCENTRATION; MIXED MANIA AND DEPRESSION; OUTCOME ASSESSMENT; PRIORITY JOURNAL; SCHIZOPHRENIA; BIPOLAR DISORDER; DEPRESSIVE DISORDER, MAJOR; DRUG ADMINISTRATION; DRUG INTERACTION;

ANTIPSYCHOTIC AGENTS; ARIPIPRAZOLE; BIPOLAR DISORDER; DEPRESSIVE DISORDER, MAJOR; DOPAMINE AGONISTS; DRUG ADMINISTRATION SCHEDULE; DRUG INTERACTIONS; HUMANS; PIPERAZINES; QUINOLONES; SCHIZOPHRENIA; THIOPHENES;

EID: 84946403966     PISSN: 13685031     EISSN: 17421241     Source Type: Journal    
DOI: 10.1111/ijcp.12752     Document Type: Editorial

References (40)

1. Citrome L,. Lorcaserin, phentermine topiramate combination, and naltrexone bupropion combination for weight loss: the 15-min challenge to sort these agents out. Int J Clin Pract 2014; 68: 1401-5.
2. Citrome L,. Vilazodone, levomilnacipran and vortioxetine for major depressive disorder: the 15-min challenge to sort these agents out. Int J Clin Pract 2015; 69: 151-5.
3. Otsuka. ABILIFY (Aripiprazole) Tablets, ABILIFY DISCMELT (Aripiprazole) Orally Disintegrating Tablets, ABILIFY (Aripiprazole) Oral Solution, ABILIFY (Aripiprazole) Injection for Intramuscular use Only. Prescribing Information, Revised December 2014. http://www.otsuka-us.com/Documents/Abilify.PI.pdf (accessed 7 September 2015).
4. Otsuka. REXULTI (Brexpiprazole) Tablets, for Oral use. Prescribing Information, Revised July 2015. http://www.otsuka-us.com/Products/Documents/Rexulti.PI.pdf (accessed 7 September 2015).
5. Actavis. VRAYLAR (Cariprazine) Capsules, for Oral use. Prescribing Information, Revised September 2015. http://pi.actavis.com/data
6. Otsuka. ABILIFY MAINTENA (Aripiprazole) for Extended-Release Injectable Suspension, for Intramuscular use. Prescribing Information, Revised July 2015. http://www.otsuka-us.com/Products/Documents/Abilify.M.PI.pdf. (accessed 20 September 2015).
7. Citrome L, Stensbøl TB, Maeda K,. The preclinical profile of brexpiprazole: what is its clinical relevance for the treatment of psychiatric disorders? Expert Rev Neurother 2015 15: 1219-29.
8. Shapiro DA, Renock S, Arrington E, et al., Aripiprazole, a novel atypical antipsychotic drug with a unique and robust pharmacology. Neuropsychopharmacology 2003; 28: 1400-11.
9. Maeda K, Sugino H, Akazawa H, et al., Brexpiprazole I: in vitro and in vivo characterization of a novel serotonin-dopamine activity modulator. J Pharmacol Exp Ther 2014; 350: 589-604.
10. Kiss B, Horváth A, Némethy Z, et al., Cariprazine (RGH-188), a dopamine D(3) receptor-preferring, D(3)/D(2) dopamine receptor antagonist-partial agonist antipsychotic candidate: in vitro and neurochemical profile. J Pharmacol Exp Ther 2010; 333: 328-40.
11. Citrome L,. Cariprazine: chemistry, pharmacodynamics, pharmacokinetics, and metabolism, clinical efficacy, safety, and tolerability. Expert Opin Drug Metab Toxicol 2013; 9: 193-206.
12. Kane JM, Carson WH, Saha AR, et al., Efficacy and safety of aripiprazole and haloperidol versus placebo in patients with schizophrenia and schizoaffective disorder. J Clin Psychiatry 2002; 63: 763-71.
13. Potkin SG, Saha AR, Kujawa MJ, et al., Aripiprazole, an antipsychotic with a novel mechanism of action, and risperidone vs placebo in patients with schizophrenia and schizoaffective disorder. Arch Gen Psychiatry 2003; 60: 681-90.
14. McEvoy JP, Daniel DG, Carson WH Jr, McQuade RD, Marcus RN,. A randomized, double-blind, placebo-controlled, study of the efficacy and safety of aripiprazole 10, 15 or 20 mg/day for the treatment of patients with acute exacerbations of schizophrenia. J Psychiatr Res 2007; 41: 895-905.
15. Cutler AJ, Marcus RN, Hardy SA, O'Donnell A, Carson WH, McQuade RD,. The efficacy and safety of lower doses of aripiprazole for the treatment of patients with acute exacerbation of schizophrenia. CNS Spectr 2006; 11: 691-702.
16. Sachs G, Sanchez R, Marcus R, et al., Aripiprazole in the treatment of acute manic or mixed episodes in patients with bipolar I disorder: a 3-week placebo-controlled study. J Psychopharmacol 2006; 20: 536-46.
17. Keck PE Jr, Marcus R, Tourkodimitris S, et al., A placebo-controlled, double-blind study of the efficacy and safety of aripiprazole in patients with acute bipolar mania. Am J Psychiatry 2003; 160: 1651-8.
18. Keck PE, Orsulak PJ, Cutler AJ, et al., Aripiprazole monotherapy in the treatment of acute bipolar I mania: a randomized, double-blind, placebo- and lithium-controlled study. J Affect Disord 2009; 112: 36-49.
19. Young AH, Oren DA, Lowy A, et al., Aripiprazole monotherapy in acute mania: 12-week randomised placebo- and haloperidol-controlled study. Br J Psychiatry 2009; 194: 40-8.
20. Vieta E, T'joen C, McQuade RD, et al., Efficacy of adjunctive aripiprazole to either valproate or lithium in bipolar mania patients partially nonresponsive to valproate/lithium monotherapy: a placebo-controlled study. Am J Psychiatry 2008; 165: 1316-25.
21. Marcus RN, McQuade RD, Carson WH, et al., The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: a second multicenter, randomized, double-blind, placebo-controlled study. J Clin Psychopharmacol 2008; 28: 156-65.
22. Berman RM, Marcus RN, Swanink R, et al., The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: a multicenter, randomized, double-blind, placebo-controlled study. J Clin Psychiatry 2007; 68: 843-53.
23. Correll CU, Skuban A, Ouyang J, et al., Efficacy and safety of brexpiprazole for the treatment of acute schizophrenia: a 6-week randomized, double-blind, placebo-controlled trial. Am J Psychiatry 2015; 172: 870-80.
24. Kane JM, Skuban A, Ouyang J, et al., A multicenter, randomized, double-blind, controlled phase 3 trial of fixed-dose brexpiprazole for the treatment of adults with acute schizophrenia. Schizophr Res 2015; 164: 127-35.
25. Thase ME, Youakim JM, Skuban A, et al., Efficacy and safety of adjunctive brexpiprazole 2 mg in major depressive disorder: a phase 3, randomized, placebo-controlled study in patients with inadequate response to antidepressants. J Clin Psychiatry 2015; 76: 1224-31.
26. Thase ME, Youakim JM, Skuban A, et al., Adjunctive brexpiprazole 1 and 3 mg for patients with major depressive disorder following inadequate response to antidepressants: a phase 3, randomized, double-blind study. J Clin Psychiatry 2015 76: 1232-40.
27. Durgam S, Starace A, Li D, et al., An evaluation of the safety and efficacy of cariprazine in patients with acute exacerbation of schizophrenia: a phase II, randomized clinical trial. Schizophr Res 2014; 152: 450-7.
28. Cutler AJ, Mokliatchouk O, Laszlovszky I, Migliore R, Durgam S,. Cariprazine in Acute Exacerbation of Schizophrenia: A Fixed-Dose Phase III, Randomized, Double-Blind, Placebo- and Active-Controlled Trial. Poster Presentation NR10-12. 168th Annual Meeting of the American Psychiatric Association, San Francisco, California, May 18-22, 2013.
29. Kane JM, Zukin S, Wang Y, et al., Efficacy and safety of cariprazine in acute exacerbation of schizophrenia: results from an international, phase III clinical trial. J Clin Psychopharmacol 2015; 35: 367-73.
30. Calabrese JR, Keck PE Jr, Starace A, et al., Efficacy and safety of low- and high-dose cariprazine in acute and mixed mania associated with bipolar I disorder: a double-blind, placebo-controlled study. J Clin Psychiatry 2015; 76: 284-92.
31. Durgam S, Starace A, Li D, et al., The efficacy and tolerability of cariprazine in acute mania associated with bipolar I disorder: a phase II trial. Bipolar Disord 2015; 17: 63-75.
32. Sachs GS, Greenberg WM, Starace A, et al., Cariprazine in the treatment of acute mania in bipolar I disorder: a double-blind, placebo-controlled, phase III trial. J Affect Disord 2015; 174: 296-302.
33. Citrome L, Ketter TA,. When does a difference make a difference? Interpretation of number needed to treat, number needed to harm, and likelihood to be helped or harmed. Int J Clin Pract 2013; 67: 407-11.
34. Citrome L,. Brexpiprazole for schizophrenia and as adjunct for major depressive disorder: a systematic review of the efficacy and safety profile for this newly approved antipsychotic-what is the number needed to treat, number needed to harm and likelihood to be helped or harmed? Int J Clin Pract 2015; 69: 978-97.
35. Berman RM, Fava M, Thase ME, et al., Aripiprazole augmentation in major depressive disorder: a double-blind, placebo-controlled study in patients with inadequate response to antidepressants. CNS Spectr 2009; 14: 197-206.
36. Hobart M, Ouyang J, Forbes A, et al., Efficacy and Safety of Brexpiprazole (OPC-34712) as Maintenance Treatment in Adults With Schizophrenia: A Randomized, Double-Blind, Placebo-Controlled Study. Poster Presentation. American Society of Clinical Psychopharmacology Annual Meeting, Miami, Florida, June 22-25, 2015.
37. Durgam S, Earley W, Li R, et al., Long-Term Cariprazine Treatment for the Prevention of Relapse in Patients With Schizophrenia: A Double-Blind, Placebo-Controlled Trial. Poster Presentation. 28th Congress of the European College of Neuropsychopharmacology, Amsterdam, the Netherlands, August 29-September 1, 2015.
38. Debelle M, Németh G, Szalai E, et al., Cariprazine as Monotherapy for the Treatment of Schizophrenia Patients With Predominant Negative Symptoms: A Double-Blind, Active Controlled Trial. Poster Presentation. 28th Congress of the European College of Neuropsychopharmacology, Amsterdam, Netherlands, August 29-September 1, 2015.
39. Citrome L,. Brexpiprazole: a new dopamine D2 receptor partial agonist for the treatment of schizophrenia and major depressive disorder. Drugs Today (Barc) 2015; 51: 397-414.
40. Citrome L, Kantrowitz J,. Antipsychotics for the treatment of schizophrenia: likelihood to be helped or harmed, understanding proximal and distal benefits and risks. Expert Rev Neurother 2008; 8: 1079-91.